CAM
ADVM

ClariVest Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

ClariVest Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,261
Closed -$246K – 734
2020
Q4 		$246K Sell
2,261
-3,089
-58% -$382K 0.01% 481
2020
Q3 		$551K Sell
5,350
-242
-4% -$36.2K 0.02% 348
2020
Q2 		$1.17M Sell
5,592
-2,682
-32% -$475K 0.03% 303
2020
Q1 		$809K Buy
+8,274
New +$965K 0.02% 330
2018
Q4 		– Sell
-6,890
Closed -$416K – 692
2018
Q3 		$416K Buy
6,890
+1,020
+17% +$57.3K 0.01% 510
2018
Q2 		$311K Buy
5,870
+50
+0.9% +$3.01K 0.01% 547
2018
Q1 		$337K Buy
+5,820
New +$362K 0.01% 542

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ClariVest Asset Management's ADVM Position: Q1 2021 in Review

ClariVest Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2021, closing a stake of 2,261 shares — an estimated $246K sold.

ClariVest Asset Management first reported a position in ADVM in Q1 2018 and held it in 7 quarters. The position peaked at $1.17M in Q2 2020. 132 funds tracked by Wall St. Rank hold ADVM as of Q1 2021.

  • ClariVest Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 2,261 Adverum Biotechnologies shares in Q1 2021, an estimated $246K.
  • ClariVest Asset Management first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 7 quarters.
  • ClariVest Asset Management's Adverum Biotechnologies position peaked at $1.17M in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2021.

Based on ClariVest Asset Management's 13F filing for Q1 2021, filed 13 May 2021.